Plain-English translation of NCT07530094 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination approach for esophageal squamous cell carcinoma — a type of esophageal cancer that is advanced and cannot be removed with surgery. The study combines standard radiation and chemotherapy with a newer immunotherapy medication called , which helps your immune system fight cancer cells. Researchers believe this combination may help more patients achieve better long-term survival.
Standard radiation and chemotherapy have helped some patients with this type of cancer, but overall results remain limited — only about 20% of patients survive 5 years, and many experience cancer recurrence. Early research suggests that adding immunotherapy to this standard treatment may significantly improve these outcomes, and this trial will test whether this approach works.
You likely qualify if…
You likely don't qualify if…
You will receive two cycles of chemotherapy drugs (nab-paclitaxel and carboplatin) given every 3 weeks, combined with radiation therapy (18 treatments over 3–4 weeks) and the immunotherapy medication . After this phase, you may receive additional chemotherapy cycles depending on your overall health. Following completion of these treatments, you will continue receiving the immunotherapy medication as maintenance therapy every 3 weeks for up to 12 months. Your doctors will monitor your progress with scans and blood tests throughout the trial.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China